Pilot Study of Galantamine to Treat Metabolic Syndrome in People With Chronic Traumatic Spinal Cord Injury (SCI)

Inclusion Criteria:

* Adults aged 21-75 years (male or female)
* Chronic (≥1 year post injury) traumatic non-progressive spinal cord injury (SCI)
* Wheelchair user for community mobility
* Injury level of tetraplegia (cervical level) or paraplegia (all levels)
* SCI-specific obesity indicated by waist circumference ≥94 cm
* Resting heart rate \>45 bpm based on 10 measurements over 10 minutes
* Without clinically significant cardiovascular abnormalities as indicated by 12-lead ECG
* Tolerable bowel routine indicated by a score of \<10 on the International SCI Bowel Function Data Set (ISCI-BDS)
* Metabolic Syndrome (MetS) defined by the presence of at least three of the following: (1) obesity indicated by SCI-specific waist circumference ≥94 cm, (2) elevated fasting glucose ≥100 mg/dL, (3) dyslipidemia: high triglycerides ≥150 mg/dL or low HDL cholesterol \<40 mg/dL for men and \<50 mg/dL for women, (4) C-reactive protein (CRP) levels \>1 mg/dL
* Able to understand and communicate in English at the level of describing adverse event frequency and severity and completing validated outcome measures
* Willingness to comply with all study procedures and availability for the duration of the study
* Provision of signed and dated informed consent form

Exclusion Criteria:

* Diagnosis of neurological injury or condition other than SCI
* Progressive condition that would be expected to change neurological status
* Signs and symptoms of cardiovascular disease or cardiac arrhythmias
* Resting heart rate \<45 bpm
* Score of 10 or greater on the ISCI-BDS v2.1 indicating moderate to severe neurogenic bowel dysfunction
* Severe concurrent medical disease, condition, or illness judged to be contraindicated by the site physician
* Psychopathology documented in the medical record or history that may conflict with study objectives
* Pregnancy (participant reported or determined by clinical lab test), women who plan to become pregnant, or women who are nursing during the study
* Active cancer or currently in treatment for cancer
* Triglyceride levels ≥400 mg/dL
* Chronic use of medications with known or probable interactions with galantamine
* Enrolled in another research study that is likely to interfere with conduct or results of the current study
* Any other reason the site physician feels that participation is contraindicated